by Stacey Johnson | Oct 20, 2017
In what feels like back-to-back news, the U.S. Food and Drug Administration (FDA) has approved two gene therapies for cancer. The actual announcements happened seven weeks apart, but for patients, manufacturers, investors and shareholders, it’s like Christmas – over...
by Stacey Johnson | Oct 6, 2017
Do you recognize the name Timothy Caulfield? How about if I tell you that he took on Gwyneth Paltrow and her Goop empire in his popular 2015 book Is Gwyneth Paltrow Wrong About Everything? Caulfield is a professor of health law and science policy at the University of...
by Sara M. Nolte | Sep 12, 2017
Over two years ago, an article published in Science took the Internet and media by storm. The paper, “Variation in cancer risk among tissues can be explained by the number of stem cell divisions,” better known as “The ‘Bad Luck’ Cancer Study,” used mathematical...
by Stacey Johnson | Aug 25, 2017
On Tuesday, August 29, Signals is hosting a blog carnival on the topic Right to Try. Before you read the perspectives of the contributing bloggers, here’s what President Trump thinks about the legislation and the Goldwater Institute’s reaction. It’s the Institute that...
by Stacey Johnson | Jul 14, 2017
I’ve been thinking about unapproved stem cell treatments a lot recently. First, I read this article that hailed the arrival of stem cell treatments in a small community in western Canada. There were many statements in the article that concerned me, but I only...
by Stacey Johnson | May 26, 2017
Recently, a friend posted on Facebook the news about her teenage son who, a year ago, had been suffering from an undiagnosed condition. Her son’s doctor didn’t treat the symptoms very seriously until the mother insisted something was wrong and implored him to identify...
Comments